XPH

SPDR S&P Pharmaceuticals ETF
A

39
*Unless otherwise stated, data provided by FactSet.

XPH Fund Description

XPH tracks an equal-weighted index of US pharmaceutical companies.

XPH Factset Analytics Insight

XPH offers equal-weighted exposure to roughly 30 US pharmaceutical companies, stretching across all market-cap sizes. XPH's weighting scheme causes it to be far less concentrated than the industry, which is dominated by a handful of mega-cap names like J&J, Pfizer and Merck. It also introduces a heavy tilt to mid- and small-caps, which makes for a rather volatile fund relative to the industry. XPH sees significant daily trading volume with small spreads, and underlying liquidity is excellent for block trades. It's also a very Efficient fund, with a low fee and tight tracking that lags by less than XPH's expense ratio. Overall, XPH is a solid way to capture a less concentrated version of the pharma market.

XPH MSCI ESG Analytics Insight

SPDR S&P Pharmaceuticals ETF has an MSCI ESG Fund Rating of BB based on a score of 3.71 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. SPDR S&P Pharmaceuticals ETF ranks in the 16th percentile within its peer group and in the 25th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

XPH MSCI FaCS and Factor Box

MSCI FaCS is a standard method for evaluating and reporting the Factor characteristics of equity portfolios including ETFs. The Factor Box includes 6 Factors that MSCI has identified that historically provided a return premium. On the vertical axis, the Factor Groups, are displayed and the horizontal axis displays the Factor exposure, overweight, underweight or neutral.

XPH Charts And Performance

Price Chart ($)
Total Return Chart (%)
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
Compare
Reset
Select ETFs to compare their performance:
PERFORMANCE [as of 09/13/19] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
XPH 2.45% -0.88% 2.21% -23.06% -5.73% -3.60% 10.57%
XPH (NAV) 1.23% -1.30% 2.00% -23.27% -5.35% -3.60% 10.57%
S&P Pharmaceuticals Select Industry 1.23% -1.10% 2.23% -23.05% -5.19% -3.44% 10.57%
Thomson Reuters US Pharmaceuticals -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

XPH Summary Data

SPDR
06/19/06
Open-Ended Fund
0.35%
$172.09M
$2.09M
0.10%

XPH Portfolio Data

$48.76B
-5.08
2.06
0.61%
09/23/19
41

XPH Index Data

S&P Pharmaceuticals Select Industry
Equal
Market Cap
Thomson Reuters US Pharmaceuticals

XPH Portfolio Management

0.35%
-0.19%
-0.07%
-0.26%

XPH Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

XPH Fund Structure

Open-Ended Fund
No
Yes
100% / 0%
N/A
N/A
Low
Daily
Cboe Book Viewer
Top Of Book
Last 10 Trades
Bats BZX Real-time Quote -
Daily Spread
Premium/Discount
Volume

XPH Factset Analytics Block Liquidity

As of 09/16/19
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of XPH. XPH is rated a 5 out of 5.

XPH Tradability

56,339
$2.09M
32,819
$1.24M
0.10%
$0.04
-0.03%
0.18% / -0.29%
None
100.00%
50,000
0.66
0.01%
0.16%
290
$37.34
5

XPH Sector/Industry Breakdown


XPH
Segment Benchmark
53.50%
89.61%
15.23%
--
10.58%
0.72%
9.69%
4.13%
6.70%
--
2.00%
0.17%
1.55%
--
0.75%
--

XPH Countries


XPH
Segment Benchmark
100.00%
100.00%

XPH Regions


XPH
Segment Benchmark
100.00%
100.00%

XPH Economic Development


XPH
Segment Benchmark
100.00%
100.00%

XPH Performance Statistics

0.57
1.03
1.08
1.03
1.00%
Thomson Reuters US Pharmaceuticals

XPH MSCI ESG Ratings

BB
3.71 / 10
24.89
16.37
--
12.02%
33.22

XPH Benchmark Comparison Holdings

41
48
26
31.90%

XPH Benchmark Comparison Summary


XPH
Segment Benchmark
41
48
$48.76B
$180.15B
-5.08
24.64
2.06
4.86
0.84%
2.61%
Medium
High

XPH Benchmark Comparison Market Cap Size


XPH
Segment Benchmark
31.80%
95.82%
32.55%
2.91%
28.41%
1.10%
7.24%
0.18%